ArticleBMC veterinary research2025
Isolation and characterization of Pseudomonas phage HJ01 and its therapeutic efficacy in canine pyoderma.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Isolation and characterization of a lytic bacteriophage against Staphylococcus aureus.BMC veterinary research · 2026Article
- Genomic, Evolutionary and Phenotypic Insights intoViruses · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundPseudomonas aeruginosa is a major pathogen in canine pyoderma, with increasing antibiotic resistance necessitating the development of alternative therapies. This study aimed to isolate and characterize a lytic phage targeting multidrug-resistant P. aeruginosa and evaluate its therapeutic efficacy in a canine pyoderma model. The key methods include isolation of phage HJ01 from wastewater, identification of genomic and biological characteristics, and subcutaneous injection of HJ01 in a canine pyoderma model induced by P. aeruginosa.
resultsThe host strain GDPA-01 exhibited multidrug resistance, with a 75% resistance gene detection rate, and harbored virulence genes such as exoU and exoT. Phage HJ01, classified as Pakpunavirus, exhibited optimal activity at pH 6.0-8.0, thermal stability up to 50 °C, a latent period of 20 min, and a burst size of 52 PFU/cell. In vivo, compared with the controls, HJ01 significantly reduced pruritus, cytology, and skin lesion scores (p < 0.05). Histopathology confirmed that in dogs treated with HJ01, epidermal repair was accelerated and inflammation was reduced.
conclusionsHJ01 emerges as a promising therapeutic candidate for managing multidrug-resistant P. aeruginosa infections in companion animals. This study pioneers the application of phage therapy in canine pyoderma, highlighting its potential to mitigate antibiotic overuse and address public health risks associated with zoonotic multidrug-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.